Nail Psoriasis and Quality-of-Life Measurement in Clinical Trials: Call for the Use of Nail-Specific Instruments Christine BlomeMatthias AugustinToni Maria Klein Current Opinion Open access 12 August 2021 Pages: 747 - 755
Psychosocial Effects of Vitiligo: A Systematic Literature Review Khaled EzzedineViktoria EleftheriadouAmit G. Pandya Systematic Review Open access 23 September 2021 Pages: 757 - 774
Appraisal of Proactive Topical Therapy in Atopic Dermatitis: Pros and Cons Anne Sofie FrølundeJacob Pontoppidan ThyssenChristian Vestergaard Review Article 28 July 2021 Pages: 775 - 783
The Use of Lasers and Light Devices in Acne Management: An Update Monica K. LiChaocheng LiuJeffrey T. S. Hsu Review Article 21 July 2021 Pages: 785 - 800
Investigational Treatments for Epidermolysis Bullosa Ping-Chen HouHan-Tang WangChao-Kai Hsu Review Article 22 July 2021 Pages: 801 - 817
Sunscreens and Photoaging: A Review of Current Literature Linna L. GuanHenry W. LimTasneem F. Mohammad Review Article 13 August 2021 Pages: 819 - 828
The Pathogenesis and Management of Acne-Induced Post-inflammatory Hyperpigmentation Nada ElbulukPearl GrimesSewon Kang Review Article 01 September 2021 Pages: 829 - 836
Steroid Phobia: A Review of Prevalence, Risk Factors, and Interventions Marissa ContentoAbigail ClineMarian Russo Review Article 21 July 2021 Pages: 837 - 851
Ceramides in Skin Health and Disease: An Update Yoshikazu UchidaKyungho Park Review Article 20 July 2021 Pages: 853 - 866
Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts Scott GuenthnerWendy McFaldaMelissa Olivadoti Original Research Article Open access 13 September 2021 Pages: 867 - 875
Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial Yan ZhaoLitao ZhangJianzhong Zhang Original Research Article 09 August 2021 Pages: 877 - 889
DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020 Patrick M. JedlowskiMahdieh F. JedlowskiMaryam T. Fazel Original Research Article 21 July 2021 Pages: 891 - 900
Comment on: Drug Survival of IL‑12/23, IL‑17 and IL‑23 Inhibitors for Psoriasis Treatment: A Retrospective Multi‑Country, Multicentric Cohort Study Emma BorgHenrik Thoning Letter to the Editor Open access 27 October 2021 Pages: 901 - 902
Authors’ reply to Borg and Thoning: “Comment on: Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study” Tiago TorresAndrea ChiricozziLuis Puig Letter to the Editor 27 October 2021 Pages: 903 - 904
Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program Eric L. SimpsonJonathan I. SilverbergSusan Johnson Correction 13 October 2021 Pages: 905 - 905
